ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases

Advanced therapies have transformed the treatment of inflammatory bowel disease; however, many patients fail to respond, highlighting the need for therapies tailored to the underlying cell and molecular disease drivers. The first-in-class oral molecule ABX464 (obefazimod), which selectively upregula...

Descripción completa

Detalles Bibliográficos
Autores principales: Apolit, Cécile, Campos, Noëlie, Vautrin, Audrey, Begon-Pescia, Christina, Lapasset, Laure, Scherrer, Didier, Gineste, Paul, Ehrlich, Hartmut, Garcel, Aude, Santo, Julien, Tazi, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132720/
https://www.ncbi.nlm.nih.gov/pubmed/36573890
http://dx.doi.org/10.14309/ctg.0000000000000560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132720/
https://www.ncbi.nlm.nih.gov/pubmed/36573890
http://dx.doi.org/10.14309/ctg.0000000000000560

Ejemplares similares